BIOTECH MARKET :

WORLD VS. BANGLADESH

Tonmoy Kumar Mondol

1
1

BIOTECH MARKET :
WORLD VS. BANGLADESH
Outline

Brief History

Ernst & Young ,Review,

2015

October 29, 2015

Asia-Pacific Biotechnology Report

Globally the biotechnology industry is

dominated by firms in North America
particularly USA and Canada (See Table 2.1)
and Europe. As the table below indicates the AP
region is a distant third in the global
biotechnology industry. In all parameters North
America is leading. The share of AP in the global
revenue is less than 10 per cent.

Some countries in the AP region have evolved policy

measures (See table 2.2) and are investing heavily
in this and are competing with other major players
like USA and Europe for their share in the global
market.

Asia-Pacific Biotechnology Rep

Asia-Pacific Biotechnology Report

While the number of firms cannot be the sole indicator of the

biotechnology industry, it does give an idea. In many countries
industry is in nascent stages while in some there is a well
diversified biotechnology industry. Asia-Pacific Biotechnology Rep

FOCUS: INDIA
MAKE IN INDIA Program,2014

Third biggest biotech industry in the Asia-Pacific

region.
Second highest number of USFDAapproved
plants.
USD 3.7 Billion to be spent on biotechnology from
2012-17.
No. 1 producer of Hepatitis B vaccine
recombinant.
USD 100 Billion industry by 2025.

FOCUS: INDIA
JAN 16

FOCUS: INDIA
JAN 16

FOCUS: INDIA
JAN 16

TOP 3 BIOTECH
COMPANIES

FOCUS: BANGLADESH
Bangladesh is yet at the rudimentary stage.(Medical
Biotechnology)
Institutions engaged in R&D on medical biotechnology are
ICDDR,B & INCEPTA
Biotechnology Resource Book 2010

Bangladesh among top three in biotech crops growth in 2014

Dhaka Tribune

96% of countrys requirement of medicine is manufactured

domestically and only 4% is imported which are mainly
biopharmaceuticals.

FOCUS: BANGLADESH
Biopharmaceutical Products
Recombinant human Erythropoietin
Recombinant human Insulin
Low molecular weight heparin (Enoxaparin)
Tissue Plasminogen Activator (Alteplase)
Vaccines (Hepatitis B, Typhoid, Rabies vaccine etc.)
Follicle stimulating hormone products
Interferone
Steptokinase
Hyaluronic acid
Interleukin
Anticancer drugs
Monoclonal antibody

FOCUS: BANGLADESH

Market Analysis:
Biopharmaceutical

Market Analysis:
Biopharmaceutical

FOCUS: BANGLADESH
Market status of Major Biopharmaceutical products
Products

Revenue Per Year (In

Crore Taka)

Growth

Vaccine

52 .57

Human insulin

36.50

14.54 %

Erythropoietin

7.05

16.79 %

Low molecular
heparin

14.73

2.71 %

Systemic hormone

142.84

13.50 %

Anabolic hormones

11.62

32.13 %
IMS Health 3Q, 2015

Market Analysis:
Biopharmaceutical

FOCUS: BANGLADESH
Market status of Major Biopharmaceutical products
Products

Major Players

Vaccine

INCEPTA, GSK

Human insulin

Novo Nordisk (Major), INCEPTA,

POPULAR (Minor)

Erythropoietin

INCEPTA

Heparin

ARISTOPHARMA, DRUG
INTERNATIONAL

Hormone

NUVISTA (Major), SQUARE,

INCEPTA,GSK (Minor)
IMS Health 3Q, 2015

FOCUS: BANGLADESH>HUMAN INSULIN> INCEPTA

Market Analysis:
Biopharmaceutical

INSULIN MARKET SEGMENTATION

Novo Nordisk

SANOFI
BANGLADESH
IMS Health 3Q, 2015

FOCUS: BANGLADESH>HUMAN INSULIN> INCEPTA

Market Analysis:
Biopharmaceutical

TWO BRANDS FOR TWO MAJOR COMPETITORS

MARKET PENETRATION
PRODUCT CONCEPT

MAXSULIN

VIBRENTA

FOCUS: BANGLADESH>HUMAN INSULIN> INCEPTA

MARKET PENETRATION

Market Analysis:
Biopharmaceutical

mph-bd.com

FOCUS: BANGLADESH>HUMAN INSULIN> INCEPTA

PRODUCT CONCEPT

Market Analysis:
Biopharmaceutical

FOCUS: BANGLADESH>HUMAN INSULIN> INCEPTA

PRODUCT CONCEPT

Market Analysis:
Biopharmaceutical

FOCUS: BANGLADESH>HUMAN INSULIN> INCEPTA

MIXTARD 30 (NOVO-NORDISK)
PRODUCT LAUNCH YR. 1999
MAXSULIN 30/70 (INCEPTA)
PRODUCT LAUNCH YR. 2007

Market Analysis:
Biopharmaceutical
IMS Health 3Q, 2015

FOCUS: BANGLADESH>HUMAN INSULIN> INCEPTA

LANTUS (SANOFI)
PRODUCT LAUNCH YR. 2010
VIBRENTA (INCEPTA)
PRODUCT LAUNCH YR. 2011

Market Analysis:
Biopharmaceutical
IMS Health 3Q, 2015

Bangladesh Pharma Industry has already started to prepare itself

with the technological knowledge of biopharmaceutics.
At this stage we need supply of knowledgeable & skilled
biotechnologist who can handle the technology from raw material to
finished product.

Product design
Identification of expressed proteins
Separation
Purification
Assay of the finished product

We need to acquire the technological knowledge to manufacture

different known biopharmaceutical products like Insulin,
Erythropoietin etc. in small scale laboratory settings.